Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICI Efficacy Prediction in Advanced Biliary Tract Cancer
NCT06074029Phase 2Active, not recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Dec 2021
- Primary completion
- Dec 2023
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, pembrolizumab, toripalimab in biliary tract cancer (BTC), sponsored by Peking Union Medical College Hospital. Started Dec 2021; status: active, not recruiting.
02
Drugs
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06074029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06074029.